Josephine van Dongen

Chapter 1 20 35. Quee FA, de Hoog MLA, Schuurman R, Bruijning-Verhagen P. Community burden and transmission of norovirus and rotavirus gastroenteritis: A prospective household study. Lancet Infect Dis. 2019;20(Provisionally Accepted):598-606. 36. Ruiz-Palacios GM, Pérez-Schael I,Velázquez FR, et al. Safety and Efficacy of an At- tenuatedVaccine against Severe Rotavirus Gastroenteritis . N Engl J Med . 2006;354(1):11-22. doi:10.1056/NEJMoa052434 37. Vesikari T, Matson DO, Dennehy P, et al. Safety and Efficacy of a Pentavalent Human– Bovine (WC3) Reassortant Rotavirus Vaccine. N Engl J Med. 2006;354(1):23-33. doi:10.1056/ NEJMoa052664 38. Burke RM,Tate JE, Kirkwood CD, Steele AD, Parashar UD. Current and new rotavirus vaccines. Curr Opin Infect Di s. 2019;32(5):435-444. doi:10.1097/QCO.0000000000000572 39. Xia S, Du J, Su J, et al. Efficacy, immunogenicity and safety of a trivalent live human-lamb reas- sor tant rotavirus vaccine (LLR3) in healthy Chinese infants: A randomized, double-blind, placebo-con- trolled trial. Vaccine. 2020;(xxxx). doi:10.1016/j.vaccine.2020.04.038 40. Seo H, Duan Q, ZhangW.Vaccines against gastroenteritis, current progress and challenges. Gut Microbes. 2020;11(6):1486-1517. doi:10.1080/19490976.2020.1770666 41. Matthijnssens J, Zeller M, Heylen E, et al. Higher propor tion of G2P[4] rotaviruses in vac- cinated hospitalized cases compared with unvaccinated hospitalized cases, despite high vaccine ef- fectiveness against heterotypic G2P[4] rotaviruses. Clin Microbiol Infect. 2014;20(10):O702-O710. doi:10.1111/1469-0691.12612 42. Justino MCA, Linhares AC, Lanzieri TM, et al. Effectiveness of the monovalent G1P[8] human rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil. Pedi- atr Infect Dis J. Published online 2011. doi:10.1097/INF.0b013e3182055cc2 43. Itzler R, Koch G, Matson DO, et al. Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5). BMC Pediatr. 2010;10. http://www.biomedcentral.com/1471-2431/10/42 44. Vesikari T, Karvonen A, Korhonen T, et al. Safety and immunogenicity of RIX4414 live at- tenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine. 2004;22(21):2836-2842. doi:10.1016/j.vaccine.2004.01.044 45. Vesikari T, Itzler R, Karvonen A, et al. RotaTeq??, a pentavalent rotavirus vaccine: Efficacy and safety among infants in Europe. Vaccine . Published online 2009. doi:10.1016/j.vaccine.2009.10.041 46. Salinas B, Schael IP, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J. Published online 2005. doi:10.1097/01.inf.0000178294.13954.a1 47. Madhi SA, Cunliffe NA, Steele D, et al. Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants. N Engl J Med. 2010;362(4):289-298. doi:10.1056/NEJMoa0904797 48. Chella Sindhu KN, Babji S, Ganesan SK. Impact of rotavirus vaccines in low and middle-income countries. Curr Opin Infect Dis. Published online 2017. doi:10.1097/QCO.0000000000000397 49. Clarke E, Desselberger U. Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings. Mucosal Immunol. Published online 2015. doi:10.1038/mi.2014.114 50. Omenaca F, Sarlangue J, Szenborn L, et al. Safety, Reactogenicity and Immunogenicity of the Human Rotavirus Vaccine in Preterm European Infants: A Randomized Phase IIIb Study. Pediatr Infect Dis J. 2012;31(5). doi:10.1097/INF.0b013e3182490a2c 51. Goveia MG, Rodriguez ZM, Dallas MJ, et al. Safety and Efficacy of the Pentavalent Hu- man-Bovine (WC3) Reassortant Rotavirus Vaccine in Healthy Premature Infants. Pediatr Infect Dis J.